NCT06533826: An ongoing trial by Ana C Garrido-Castro, MD
This trial is ongoing. It must report results 3 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06533826 |
|---|---|
| Title | A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 29, 2024 |
| Completion date | Jan. 1, 2028 |
| Required reporting date | Dec. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | None |